Growth Metrics

Axsome Therapeutics (AXSM) Free Cash Flow (2022 - 2026)

Axsome Therapeutics' Free Cash Flow history spans 5 years, with the latest figure at -$20.8 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 52.37% to -$20.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$71.0 million, a 40.26% increase, with the full-year FY2025 number at -$93.9 million, up 27.04% from a year prior.
  • Free Cash Flow hit -$20.8 million in Q1 2026 for Axsome Therapeutics, down from -$18.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AXSM hit a ceiling of $988000.0 in Q3 2025 and a floor of -$55.5 million in Q2 2023.
  • Historically, Free Cash Flow has averaged -$29.8 million across 5 years, with a median of -$30.2 million in 2024.
  • Biggest five-year swings in Free Cash Flow: tumbled 809.11% in 2024 and later skyrocketed 105.28% in 2025.
  • Tracing AXSM's Free Cash Flow over 5 years: stood at -$27.7 million in 2022, then decreased by 9.46% to -$30.4 million in 2023, then increased by 13.62% to -$26.2 million in 2024, then rose by 28.62% to -$18.7 million in 2025, then fell by 11.2% to -$20.8 million in 2026.
  • Business Quant data shows Free Cash Flow for AXSM at -$20.8 million in Q1 2026, -$18.7 million in Q4 2025, and $988000.0 in Q3 2025.